Compound C Inhibits Renca Renal Epithelial Carcinoma Growth in Syngeneic Mouse Models by Blocking Cell Cycle Progression, Adhesion and Invasion

Compound C (CompC), an inhibitor of AMP-activated protein kinase, reduces the viability of various renal carcinoma cells. The molecular mechanism underlying anti-proliferative effect was investigated by flow cytometry and western blot analysis in Renca cells. Its effect on the growth of Renca xenogr...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-09, Vol.23 (17), p.9675
Main Authors: Lee, Myungyeon, Ham, Na Yeon, Hwang, Chi Yeon, Jang, Jiwon, Lee, Boram, Jeong, Joo-Won, Kang, Insug, Yeo, Eui-Ju
Format: Article
Language:English
Subjects:
Adhesion
AMP-activated protein kinase
Animal models
Apoptosis
Cancer
Cell culture
Cell cycle
Cell growth
Cell viability
Extracellular signal-regulated kinase
Flow cytometry
Growth factors
Histone H3
Histones
Kidney cancer
Kinases
Metastasis
Morphology
Mortality
Phosphorylation
Platelet-derived growth factor
Platelet-derived growth factor receptors
Protein-tyrosine kinase
Proteins
Reactive oxygen species
Renal cell carcinoma
Syngeneic grafts
Tumor cells
Tumors
Tyrosine
Xenografts
Xenotransplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Compound C (CompC), an inhibitor of AMP-activated protein kinase, reduces the viability of various renal carcinoma cells. The molecular mechanism underlying anti-proliferative effect was investigated by flow cytometry and western blot analysis in Renca cells. Its effect on the growth of Renca xenografts was also examined in a syngeneic BALB/c mouse model. Subsequent results demonstrated that CompC reduced platelet-derived growth factor receptor signaling pathways and increased ERK1/2 activation as well as reactive oxygen species (ROS) production. CompC also increased the level of active Wee1 tyrosine kinase (P-Ser642-Wee1) and the inactive form of Cdk1 (P-Tyr15-Cdk1) while reducing the level of active histone H3 (P-Ser10-H3). ROS-dependent ERK1/2 activation and sequential alterations in Wee1, Cdk1, and histone H3 might be responsible for the CompC-induced G2/M cell cycle arrest and cell viability reduction. In addition, CompC reduced the adhesion, migration, and invasion of Renca cells in the in vitro cell systems, and growth of Renca xenografts in the BALB/c mouse model. Taken together, the inhibition of in vivo tumor growth by CompC may be attributed to the blockage of cell cycle progression, adhesion, migration, and invasion of tumor cells. These findings suggest the therapeutic potential of CompC against tumor development and progression.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms23179675